HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications.

Abstract
Genentech Inc and Novartis Ophthalmics AG have developed and launched the humanized anti-VEGF antibody fragment ranibizumab, a 48-kDa humanized antibody fragment that inhibits all forms of biologically active VEGF-A, for the treatment of age-related macular degeneration by intravitreal administration. Phase I to III clinical trials to confirm the role of ranibizumab in the treatment of choroidal neovascularization (phase II and III), diabetic macular edema (phase II and III), retinal venous occlusion (phase II and III), telangiectasia (phase I and II), central serous chorioretinopathy (phase I), polypoidal choroidal vasculopathy (phase I/II), conjunctival neoplasms (phase I) and von Hippel-Lindau syndrome (phase I) are ongoing.
AuthorsLaura E Lantry
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 6 Pg. 592-602 (Dec 2007) ISSN: 1464-8431 [Print] England
PMID18041670 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Ranibizumab
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Choroidal Neovascularization
  • Clinical Trials as Topic
  • Conjunctival Neoplasms
  • Diabetes Complications
  • Humans
  • Macular Edema (drug therapy)
  • Neovascularization, Pathologic (drug therapy)
  • Ranibizumab
  • Telangiectasis
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • von Hippel-Lindau Disease

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: